Israel News Beep | NewsBeep.com
  • News Beep
  • Israel
  • Headlines
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology
Israel News Beep | NewsBeep.com
Israel News Beep | NewsBeep.com
  • News Beep
  • Israel
  • Headlines
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology

Browsing Tag

Reimagine Medicine

14 posts
BBusiness
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • June 12, 2026
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
BBusiness
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Read More

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

  • May 31, 2026
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of…
BBusiness
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Read More

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

  • March 21, 2026
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…
HHealthcare
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

  • February 27, 2026
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

  • February 27, 2026
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks…
HHealthcare
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

  • February 25, 2026
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

  • February 23, 2026
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…
MMedication
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

  • February 21, 2026
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

  • February 6, 2026
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

  • January 16, 2026
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development…
HHealthcare
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis and US government reach agreement on lowering drug prices in the US

  • December 19, 2025
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

  • October 25, 2025
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker…
Israel News Beep | NewsBeep.com
www.newsbeep.com